This morning's press release appears to indicate t
Post# of 148158
Quote:
“This is an exciting period for CytoDyn. With the continuation of the BLA resubmission, the near-term initiation of two important COVID-19 trials in Brazil , and possibly a strong clinical trial in the U.S. for COVID-19 long-haulers, the next two to three months could be transformative for the Company.”/quote]
https://www.cytodyn.com/investors/news-events...v-bla-dose